Yusha Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yusha Chen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Sheng Wang
Department of Dermatology, West China Hospital Sichuan University Chengdu China
3 shared publications- Zhongtao Li
Department of Dermatology, West China Hospital Sichuan University Chengdu China
3 shared publications Chuangwen Liu
Department of Pediatrics West China Second University Hospital, Sichuan University Chengdu China
2 shared publications- Deyu Song
Department of Dermatology West China Hospital, Sichuan University Chengdu China
2 shared publications Jia Geng
Institute of Rare Diseases, West China Hospital Sichuan University Chengdu China
2 shared publications- Sheng Wang
Department of Neurobiology Hebei Medical University Shijiazhuang China
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 16, 1-14
Genotype–Phenotype Correlations and Clinical Outcomes of Spesolimab in Acrodermatitis Continua of Hallopeau: A Multicenter Retrospective Cohort Study
Purpose: To explore genotype–phenotype associations of IL36RN variants and clinical outcomes of spesolimab treatment in acrodermatitis continua of Hallopeau (ACH). Patients and methods: This multicenter retrospective study included 14 ACH patients with IL36RN genotyping from 2019 to 2025. Clinical features were compared across all genotypes. Medical records of individuals who received spesolimab were reviewed to describe treatment responses, with a follow-up observation period up to 56 weeks. Results: Compared with monoallelic or wild-type genotypes, biallelic IL36RN variants were associated with earlier disease onset age (23 vs 48 and 47 years, P < 0.05) and higher baseline disease severity (median GPPGA score, 4 vs 3 and 2, P < 0.001). Among 6 patients with biallelic, refractory ACH who received spesolimab, including 3 isolated cases that were administered at a 450-mg dose, overall percentage improvement across disease activity and patient-reported measures occurred rapidly, reaching 54% at week 1 and 74% at week 4. Relapse occurred in 4 patients between weeks 31 and 44, with disease activity remaining lower than baseline and improvement observed after re-treatment. Conclusion: Spesolimab was associated with clinical improvement in refractory ACH with biallelic IL36RN mutations, including isolated ACH treated with a 450-mg dose, supporting further evaluation of dose individualization below the approved 900-mg regimen for GPP flares.
- 1 July 2026
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 16, 1-14
Open AccessGenotype–Phenotype Correlations and Clinical Outcomes of Spesolimab in Acrodermatitis Continua of Hallopeau: A Multicenter Retrospective Cohort Study
Purpose: To explore genotype–phenotype associations of IL36RN variants and clinical outcomes of spesolimab treatment in acrodermatitis continua of Hallopeau (ACH). Patients and methods: This multicenter retrospective study included 14 ACH patients with IL36RN genotyping from 2019 to 2025. Clinical features were compared across all genotypes. Medical records of individuals who received spesolimab were reviewed to describe treatment responses, with a follow-up observation period up to 56 weeks. Results: Compared with monoallelic or wild-type genotypes, biallelic IL36RN variants were associated with earlier disease onset age (23 vs 48 and 47 years, P < 0.05) and higher baseline disease severity (median GPPGA score, 4 vs 3 and 2, P < 0.001). Among 6 patients with biallelic, refractory ACH who received spesolimab, including 3 isolated cases that were administered at a 450-mg dose, overall percentage improvement across disease activity and patient-reported measures occurred rapidly, reaching 54% at week 1 and 74% at week 4. Relapse occurred in 4 patients between weeks 31 and 44, with disease activity remaining lower than baseline and improvement observed after re-treatment. Conclusion: Spesolimab was associated with clinical improvement in refractory ACH with biallelic IL36RN mutations, including isolated ACH treated with a 450-mg dose, supporting further evaluation of dose individualization below the approved 900-mg regimen for GPP flares.
- 4 May 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (10)
Dupilumab for pruritus associated with dystrophic epidermolysis bullosa: A systematic review
- 4 May 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (10)
Dupilumab for pruritus associated with dystrophic epidermolysis bullosa: A systematic review
- 22 October 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (3) , 531-535
Biallelic pathogenic variants in the LSS gene cause congenital alopecia‐cataract syndrome
Biallelic variants in the LSS gene have been reported in individuals affected by alopecia‐intellectual disability syndrome 4, cataract 44, hypotrichosis 14, and palmoplantar keratoderma‐congenital alopecia syndrome type 2. The present report described a Chinese girl with congenital alopecia universalis, cataract, esotropia, and nystagmus caused by compound heterozygous variants of c.1025T>G (p.Ile342Ser) and previously unreported c.1011G>A (p.Pro337=) in the LSS gene. Minigene assay confirmed the synonymous variant Pro337= at the edge of exon 9 could produce a novel splice site, leading to a 46‐bp insertion of the 5′ sequence of the intron 9, likely resulting in a frameshift effect. We consider that the clinical manifestations of this case represent a new type of LSS‐related disease, namely congenital alopecia‐cataract syndrome (CACS). Our data expand the phenotypic and genetic spectrum of LSS‐related diseases.
- 22 October 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (3) , 531-535
Biallelic pathogenic variants in the LSS gene cause congenital alopecia‐cataract syndrome
Biallelic variants in the LSS gene have been reported in individuals affected by alopecia‐intellectual disability syndrome 4, cataract 44, hypotrichosis 14, and palmoplantar keratoderma‐congenital alopecia syndrome type 2. The present report described a Chinese girl with congenital alopecia universalis, cataract, esotropia, and nystagmus caused by compound heterozygous variants of c.1025T>G (p.Ile342Ser) and previously unreported c.1011G>A (p.Pro337=) in the LSS gene. Minigene assay confirmed the synonymous variant Pro337= at the edge of exon 9 could produce a novel splice site, leading to a 46‐bp insertion of the 5′ sequence of the intron 9, likely resulting in a frameshift effect. We consider that the clinical manifestations of this case represent a new type of LSS‐related disease, namely congenital alopecia‐cataract syndrome (CACS). Our data expand the phenotypic and genetic spectrum of LSS‐related diseases.
- 8 October 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (3) , 526-530
A case of peeling skin syndrome type 1 with novel CDSN gene variation successfully treated with upadacitinib
Peeling skin syndrome type 1 (PSS1) is an autosomal recessive genodermatosis caused by the CDSN gene loss‐of‐function mutation and characterized by widespread superficial skin peeling and erythroderma with unbearable pruritus. Because of its ultra‐rarity and unclear mechanism, this rare disease has no established treatment regimen. Herein, we reported a Chinese woman who presented with congenital generalized pruritic erythroderma and exfoliation, notable for significantly elevated IgE levels. The whole exome sequencing identified an unpublished homozygous variant (c.295C>T, p.Gln99*) in the CDSN gene, confirming the diagnosis of PSS1. Immunohistochemistry analysis of the affected skin confirmed the lack of corneodesmosin expression, revealed the overexpression of T helper 2 (Th2)–related cytokines harboring interleukin (IL) 4 and IL‐13. After Janus kinase 1 (JAK1) inhibitor upadacitinib administration, both the patient's skin rashes and itching symptoms were significantly alleviated. Our work expanded the PSS1‐related CDSN gene mutation spectrums, substantiated the hypothesis regarding the overexpression of Th2‐related cytokines, and uncovered the important role of JAK1 underlying PSS1. JAK1 signaling may dominate the pathogenesis in PSS1 and represent a potential therapeutic target.
- 8 October 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (3) , 526-530
A case of peeling skin syndrome type 1 with novel CDSN gene variation successfully treated with upadacitinib
Peeling skin syndrome type 1 (PSS1) is an autosomal recessive genodermatosis caused by the CDSN gene loss‐of‐function mutation and characterized by widespread superficial skin peeling and erythroderma with unbearable pruritus. Because of its ultra‐rarity and unclear mechanism, this rare disease has no established treatment regimen. Herein, we reported a Chinese woman who presented with congenital generalized pruritic erythroderma and exfoliation, notable for significantly elevated IgE levels. The whole exome sequencing identified an unpublished homozygous variant (c.295C>T, p.Gln99*) in the CDSN gene, confirming the diagnosis of PSS1. Immunohistochemistry analysis of the affected skin confirmed the lack of corneodesmosin expression, revealed the overexpression of T helper 2 (Th2)–related cytokines harboring interleukin (IL) 4 and IL‐13. After Janus kinase 1 (JAK1) inhibitor upadacitinib administration, both the patient's skin rashes and itching symptoms were significantly alleviated. Our work expanded the PSS1‐related CDSN gene mutation spectrums, substantiated the hypothesis regarding the overexpression of Th2‐related cytokines, and uncovered the important role of JAK1 underlying PSS1. JAK1 signaling may dominate the pathogenesis in PSS1 and represent a potential therapeutic target.
- 16 February 2023
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (8) , E230-E231
One recurrent heterozygous mutation of the PLCD1 gene in a Chinese family with hereditary leukonychia: A case report and genotype–phenotype correlation analysis
- 16 February 2023
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (8) , E230-E231
One recurrent heterozygous mutation of the PLCD1 gene in a Chinese family with hereditary leukonychia: A case report and genotype–phenotype correlation analysis
- 21 November 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (2) , 389-391
Enterokinase deficiency with novel TMPRSS15 gene mutation masquerading as acrodermatitis enteropathica
Enterokinase deficiency (EKD) is a rare autosomal recessive inherited disorder caused by loss-of-function mutations of the transmembrane protease serine 15 (TMPRSS15) gene. To date, only 12 cases of EKD have been described in the literature and skin involvement has seldom been described. We identified a novel homozygous nonsense mutation in the TMPRSS15 gene (c.1216C>T, p.R406*) in a female infant, who manifested with acrodermatitis enteropathica (AE)-like lesions that were dramatically relieved within 11 days after initiation of a protein-rich hydrolyzed formula. Our case shows that AE-like rashes can be a manifestation of EKD and expands the spectrum of causative mutations in the TMPRSS15 gene.
- 21 November 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (2) , 389-391
Enterokinase deficiency with novel TMPRSS15 gene mutation masquerading as acrodermatitis enteropathica
Enterokinase deficiency (EKD) is a rare autosomal recessive inherited disorder caused by loss-of-function mutations of the transmembrane protease serine 15 (TMPRSS15) gene. To date, only 12 cases of EKD have been described in the literature and skin involvement has seldom been described. We identified a novel homozygous nonsense mutation in the TMPRSS15 gene (c.1216C>T, p.R406*) in a female infant, who manifested with acrodermatitis enteropathica (AE)-like lesions that were dramatically relieved within 11 days after initiation of a protein-rich hydrolyzed formula. Our case shows that AE-like rashes can be a manifestation of EKD and expands the spectrum of causative mutations in the TMPRSS15 gene.
- 11 June 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 39 (6) , 987-989
Secondary acrodermatitis enteropathica‐like skin findings in a case of methylmalonic acidemia
Methylmalonic acidemia (MMA) is an autosomal recessive genetic disorder caused by decreased activity of methylmalonyl‐CoA mutase or metabolic disturbance of its coenzyme cobalamin, cutaneous manifestations are rare clinical signs in this disease. Herein, we describe a Chinese boy with MMA fed with a formula lacking branched‐chain amino acids presenting with erythroderma and acrodermatitis enteropathica‐like rash, a homozygous nonsense mutation c.742C>T (p.Gln248*) was identified in the MMAA gene. The pedigree exhibited a non‐Mendelian inheritance pattern which was attributed to maternal uniparental disomy on chromosome 4q26‐q34.1 of the proband, confirmed by chromosomal microarray analysis. Our case highlights the association between skin changes and nutritional deficiency due to therapeutic amino acid restrictions in MMA.
- 11 June 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 39 (6) , 987-989
Secondary acrodermatitis enteropathica‐like skin findings in a case of methylmalonic acidemia
Methylmalonic acidemia (MMA) is an autosomal recessive genetic disorder caused by decreased activity of methylmalonyl‐CoA mutase or metabolic disturbance of its coenzyme cobalamin, cutaneous manifestations are rare clinical signs in this disease. Herein, we describe a Chinese boy with MMA fed with a formula lacking branched‐chain amino acids presenting with erythroderma and acrodermatitis enteropathica‐like rash, a homozygous nonsense mutation c.742C>T (p.Gln248*) was identified in the MMAA gene. The pedigree exhibited a non‐Mendelian inheritance pattern which was attributed to maternal uniparental disomy on chromosome 4q26‐q34.1 of the proband, confirmed by chromosomal microarray analysis. Our case highlights the association between skin changes and nutritional deficiency due to therapeutic amino acid restrictions in MMA.
- 14 December 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (5) , 961-963
Clinical and dermoscopic characteristics of onychophagia and onychotillomania: a retrospective study of 63 cases
Onychophagia and onychotillomania are common forms of nail-biting and nail-picking disorders, but there is insufficient literature documenting their comparison and coexistence. In fact, overlapping features can be involved in different nail self-injuries, and significant variations also exist. We conducted a retrospective study aimed at identifying differences between onychophagia and onychotillomania, and providing more detailed findings of both conditions.
- 14 December 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (5) , 961-963
Clinical and dermoscopic characteristics of onychophagia and onychotillomania: a retrospective study of 63 cases
Onychophagia and onychotillomania are common forms of nail-biting and nail-picking disorders, but there is insufficient literature documenting their comparison and coexistence. In fact, overlapping features can be involved in different nail self-injuries, and significant variations also exist. We conducted a retrospective study aimed at identifying differences between onychophagia and onychotillomania, and providing more detailed findings of both conditions.
- Open Access
- 30 November 2021
- Published by Wiley in Experimental Dermatology
- Vol. 31 (5) , 823-824
Evaluation of human acellular amniotic membrane for promoting anterior auricle reconstruction
- 30 November 2021
- Published by Wiley in Experimental Dermatology
- Vol. 31 (5) , 823-824
Open AccessEvaluation of human acellular amniotic membrane for promoting anterior auricle reconstruction
- 15 September 2021
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (12) , E591-E593
Novel deletion of the POFUT1 gene associated with multiple seborrheic keratosis Dowling–Degos disease
- 15 September 2021
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (12) , E591-E593
Novel deletion of the POFUT1 gene associated with multiple seborrheic keratosis Dowling–Degos disease